<DOC>
	<DOCNO>NCT02459652</DOCNO>
	<brief_summary>Multicenter Prospective Phase II Study Neoadjuvant S-1 Concurrent Radiotherapy Borderline Resectable Pancreatic Cancer RATIONALE : Borderline resectable pancreatic cancer frequently relate positive surgical margin poor prognosis resection . Neoadjuvant chemoradiation intensive local effect may lead substantial local control prolongation survival borderline resectable pancreatic cancer . PURPOSE : This phase II trial ass efficacy safety neoadjuvant S-1 concurrent radiotherapy borderline resectable pancreatic cancer .</brief_summary>
	<brief_title>Neoadjuvant S-1 Concurrent Radiotherapy Borderline Resectable Pancreatic Cancer</brief_title>
	<detailed_description>S-1 : S-1 oral fluorinated pyrimidine agent contain tegafur ( FT , prodrug 5-FU ) , 5-chloro-2,4-dihydropyrimidine ( CHDP ) potassium oxonate ( Oxo ) effective gastric various type cancer . S-1 also active pancreatic cancer : S-1 demonstrate non-inferiority gemcitabine overall survival metastatic locally advanced pancreatic cancer ( LAPC ) . S-1 Concurrent radiotherapy : S-1 therapy concurrent radiation therapy ( RT ) favorable activity overall tumor response rate 37 % , well mild toxicity patient LAPC . The median survival time 2-year survival rate LAPC patient treat S-1/RT 16.2 month 26 % respectively . Definition Borderline Resectable Pancreatic Cancer : ( 1 ) Reconstructible bilateral impingement superior mesenteric vein portal vein ; ( 2 ) Tumor contact superior mesenteric artery ( SMA ) &lt; /= 180 degree ; ( 3 ) Tumor contact common hepatic artery &lt; /= 180 degree ( root gastroduodenal artery ) ; ( 4 ) Tumor contact celiac axis &lt; /= 180 degree . Tumor portal vein tumor thrombus tumor contact second jejunal SMA branch consider unresectable . Tumor contact common hepatic artery celiac axis resect distal pancreatectomy en bloc celiac axis resection , include study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Cytologic histologic proof pancreatic ductal carcinoma adenosquamous carcinoma require prior study entry . Disease assessment Multi Detectorrow Computed Tomography ( MDCT ) scan within 2 week study entry Borderline resectable pancreatic cancer No evidence metastatic disease determine chest CT scan , abdominal CT scan laparoscopy . Paraaortic lymph node metastasis consider metastatic . Age &gt; /=20 year old , &lt; /=75 year old Eastern Cooperative Oncology Group ( ECOG ) performance status 01 No prior chemotherapy radiotherapy pancreatic cancer A square 10 x 10 cm radiation field could encompass pancreatic lesion lymph node metastasis Adequate oral intake Appropriate biliary drainage obstructive jaundice Lab Values : hemoglobin concentration &gt; /= 9.0 g/dL leukocyte count &gt; /= 3,000/mm3 platelet count &gt; /= 100,000/mm3 serum total bilirubin &lt; /= 2.0 mg dL , &lt; /=3.0 mg/dL biliary drainage Aspartate Transaminase ( AST ) Alanine Transaminase ( ALT ) &lt; /= 100 U/L , &lt; /= 150 U/L biliary drainage serum albumin &gt; /= 3.0 g/dl serum creatinine &lt; /= 1.2 mg dL Creatinine clearance &gt; /= 50 ml/min Written inform consent Tumor invasion alimentary tract determine abdominal CT scan endoscopic examination Prior chemotherapy use fluoropyrimidine Prior radiation therapy abdomen Watery diarrhea Concurrent phenytoin , warfarin potassium , flucytosine treatment Presence contrast medium allergy Pulmonary fibrosis interstitial pneumonia Pleural effusion ascites Active infection Uncontrolled diabetes mellitus ( FBS &gt; /= 200mg/dL HbA1c &gt; /= 10.0 ) Active concomitant malignancy Active gastroduodenal ulcer Severe complication cardiac renal disease Regular administration systemic corticosteroid Psychiatric disorder History drug hypersensitivity Pregnant lactate woman woman childbearing age use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Borderline Resectable Pancreatic Cancer</keyword>
</DOC>